ARTIcLE InfO ______________________________________________________________ ______________________ We had investigated whether sequence variants within DKK3 gene are associated with the development of prostate cancer in a Korean study cohort. We evaluated the association between 53 single nucleotide polymorphisms (SNPs) in the DKK3 gene and prostate cancer risk as well as clinical characteristics (PSA, clinical stage, pathological stage and Gleason score) in Korean men (272 prostate cancer subjects and 173 benign prostate hyperplasia subjects) using unconditional logistic regression analysis. Of the 53 SNPs and 25 common haplotypes, 5 SNPs and 4 haplotypes were associated with prostate cancer risk (P=0.02-0.04); 3 SNPs and 2 haplotypes were significantly associated with susceptibility to prostate cancer, however 2 SNPs and 2 haplotypes exhibited a significant protective effect on prostate cancer. Logistic analyses of the DKK3 gene polymorphisms with several prostate cancer related factors showed that several SNPs were significant; three SNPs and two haplotypes to PSA level, three SNPs and two haplotypes to clinical stage, nine SNPs and two haplotype to pathological stage, one SNP and one haplotypes to Gleason score. To the author's knowledge, this is the first report documenting that DKK3 polymorphisms are not only associated with prostate cancer but also related to prostate cancer-related factors.
InTRODucTIOn
Prostate cancer is one of the most common cancers in men. Rates of detection of prostate cancer vary widely across the world, with less frequent detection in South and East Asia than in Europe and especially the United States (1, 2) . However the incidence rate of prostate cancer in Korea has rised rapidly during the last decade (3) . The etiology of prostate cancer is largely unknown, although several risk factors such as diet, occupation, sexually transmitted agents were investigated epidemiologically; the only established risk factors for prostate cancer are increased age, ethnic background and familial history (4) . Recently genome--wide association studies (GAWS) have identified more than 40 single-nucleotide polymorphisms (SNPs) on various genes or chromosomal loci that are significantly associated with prostate cancer susceptibility (5) . There is increasing interest in investigating the potential usefulness of SNPs as diagnostic and prognostic biomarkers for prostate cancer outcomes (6, 7) .
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for their roles in embryogenesis and tumorigenesis (8) . Uncontrolled Wnt signaling has been recognized as an important trait of human cancer (9) . Their activity is regulated by the secreted Wnt signaling inhibitors including Wnt antagonist families namely the secreted frizzled-related protein (sFRP), Wnt inhibitory factor 1 (Wif-1), and Dickkopf (DKK1-4) families (10) . Dickkopf homologue 3 (DKK3) gene which is located at 11p15, is proposed to function as a tumor suppressor gene since its expression is down-regulated in many types of cancer cells (11) . Inactivation of tumor-suppressive genes by either genetic or epigenetic mechanisms contributes to cancer formation. Ectopic expression of DKK3 results in decreased proliferation and is accompanied by attenuation of the mitogen-activated protein kinase pathway (12) . If DKK3 regulates the growth of normal and cancerous prostate cells, the variation in DKK3 activity may be important in the onset and progression of prostate cancer. We hypothesized that sequence variations in DKK3 are candidates for risk factors for development of prostate cancer and progression.
However to our knowledge, there have been no reports regarding DKK3 gene polymorphisms in prostate cancer. Here we investigated whether SNPs of the DKK3 gene were associated with the development of prostate cancer in a Korean cohort.
MATERIALs AnD METhODs

Study Population
Blood samples were obtained from the Korean Prostate Bank (Seoul, Korea). Both prostate cancer and benign prostatic hyperplasia (BPH) groups originated from a population of older men treated at St. Mary's Hospital (Seoul, Korea). Peripheral blood leukocyte samples for genotyping were obtained from 445 men (prostate cancer, n=272; BPH, n=173) and were stored at -80°C. BPH subjects had true biopsy for confirmation for free of prostate cancer at the time when the samples were taken according to prostate-specific antigen blood tests and digital rectal prostate exams and were excluded from the study if they had a history of prostate cancer. Prostate cancer subjects with primary, incident, histologically confirmed prostate cancer were recruited within 6 months of diagnosis. The median age of the BPH cohort was 67.3 years, and the median age of the prostate cancer cohort was 68.2 years. BPH samples were used as the control group for several reasons. First, most men have evidence of BPH by the age of 70 or 80 years; thus, the presence of some degree of BPH is "normal" at the median age of diagnosis in our prostate cancer cohort (age 67.3 years). Truly "normal" samples would thus only be obtained in a much younger control cohort, which could introduce bias. Second, the collection of blood samples requires a hospital visit and a prostate cancer screening procedure, which would only be undertaken in men with evidence of symptoms of prostate enlargement. All the study participants provided written informed consent. The institutional review board of Chung--Ang University Hospital and Catholic University Hospital approved the study. Blood samples were collected in tubes containing sodium ethylene diaminetetraacetic acid from St. Mary's Hospital in Korea. The QIA amp blood extraction kit (Qiagen, Seoul, Korea) was used for DNA extraction.
The PSA level was classified as low (PSA<4), intermediate (4≤PSA<10), or high (PSA≥10). The Gleason score was designated as low (Gleason score 2-6), intermediate (Gleason score 4+3, 3+4), or high (Gleason score 8-10) grade. The clinicopathologic regional stages were categorized as localized (Stage T1N0M0 orT2N0M0), locally advanced (Stage T3N0M0 or T4N0M0), and metastatic (TxN+ or TxM+) according to the pathologic and/ or radiologic reports. Clinical characteristics of the study population are listed in Table-1 and were similar to those of a previous Korean study (13) .
SNP Selection and Genotyping
We selected 53 SNPs from two international databases (International HapMap and National Center for Biotechnology Information dbSNPs). SNP selection from the International HapMap database (Han Chinese and Japanese) was performed as follows: (a) extraction of all genotypes from the CHB and JPN population in DKK3 gene region using HapMart of the International HapMap database (version release 27; available from: http:// www.hapmap.org); (b) calculation of minor allele frequency and linkage disequilibrium using Haplo view software (Cambridge, MA; available from: http://www.broad.mit.edu/mpg/haploview), and (c) selection of SNPs having minor allele frequency >0.05 and tagging SNPs if several SNPs showed high linkage disequilibrium >0.98. Furthermore, we added the SNPs in the DKK3 gene region from the National Center for Biotechnology Information db-SNPs. The selection criteria included location (SNPs in exons were preferred) and amino acid changes (nonsynonymous SNPs were preferred). Genotyping was performed at the multiplex level using the Illumina Golden Gate genotyping system (14) . In brief, approximately 250 ng genomic DNA extracted from the blood of each subject was used for genotyping by DNA activation, binding to paramagnetic particles, hy-bridization to oligonucleotides, washing, extension, ligation, amplification by polymerase chain reaction, and hybridization to the Bead plate in an appropriate hybridization buffer. The image intensities were scanned using the Bead Xpress Reader, and genotyped using the Genome Studio software (Illumina). The genotype quality score for retaining data was set to 0.25. A total of 53 SNPs were successfully genotyped.
statistical analysis
The SNP genotype frequencies were examined for Hardy-Weinberg equilibrium using the chi-square test, and all were found to be consistent (P>0.05) with Hardy-Weinberg equilibrium among the Korean controls. The data were analyzed using unconditional logistic regression analysis to calculate the odds ratio (OR) as an estimate of the relative risk of prostate cancer associated with SNP genotypes (15) .
To determine the association between the genotype and haplotype distributions of patients and controls, logistic analysis was performed, controlling for age (continuous value) as a covariate to eliminate or reduce any confounding influence. Significant associations were indicated (P≤0.05). Multiple comparisons were also accounted for by using per mutations to calculate the exact P values for each significant SNP (α=0.05). Lewontin's D' and the linkage disequilibrium coefficient r2 were examined to measure linkage disequilibrium between all pairs of bi-allelic loci (16) . Haplotypes were inferred from the successfully genotyped SNPs using the PHASE algorithm, version 2.0 (17), and association analysis was performed using SAS, version 9.1 (SAS Institute, Cary, NC). To achieve optimal correction for multiple testing of markers, representing SNPs in linkage disequilibrium with each other, the effective number of independent marker loci (21.3) was calculated using SNP spectral decomposition software (available from: http://genepi.qimr.edu.au/ general/daleN/SNPSpD/), a program that is based on the spectral decomposition of matrices of pair--wise linkage disequilibrium among markers (18) .
Statistical power of single associations was calculated with false positive rate of 5%, disease lifetime prevalence of 0.02%, given minor allele frequencies and sample sizes, and assuming a relative risk of 1.5, using PGA (Power for Genetic Association Analyses) software (19) .
REsuLTs
The association between DKK3 polymorphisms and the risk of prostate cancer A total of 53 SNPs from the human DKK3 gene in 272 patients with prostate cancer and 173 control subjects were successfully genotyped to determine the potential association of the gene with the development of prostate cancer (Figure-1). The genotype distributions in the control group were in Hardy-Weinberg equilibrium (P>0.05; data not shown). The measured linkage disequilibrium among 53 SNPs was determined by calculating Lewontin's D' and r 2 values; the results showed that these SNPs were divided among five haplotype blocks (Figure-2 ). The allele frequencies of each of the polymorphisms and common haplotypes were compared between the patients and the normal controls using logistic regression models. The results of the analysis revealed that five SNPs showed nominal evidence of an association at a P<0.05 level of significance (Table-2, Supplementary Table-1) . Of the five significantly associated SNPs, three (rs12421658, rs11022105, and rs4586138) showed a greater frequency in patients with prostate cancer than in the normal controls (OR 1.63, p=0.04; OR 1.54, p=0.04; and OR 1.89, p=0.02, respectively). In addition, a haplotype association test was performed on 25 common haplotypes (frequency >0.05) within the five haplotype blocks. Two haplotypes (Block2_ht3 and Block5_ht5) showed a marginal association with the risk of prostate cancer (P=0.04 and P=0.03, respectively). There were two SNPs (rs2087882 and rs1472190) and two haplotypes (Block3_ht6 and Block5_ht4) that exhibited a significant protective effect from prostate cancer (Table-2 ).
The association between DKK3 polymorphisms and PSA level in prostate cancer group
We performed analyses involving only the patients with prostate cancer. Four SNPs and two haplotypes exhibited a significant associa-tion with the PSA levels (Table-3, Supplementary  Table-2) . Two SNPs (rs16910308, rs7116879) and one haplotype (Block2_ht2) had a markedly significant effect on elevated PSA levels in the co--dominant and dominant model (OR 1.77, p=0.007 and OR 2.27, p=0.0007; OR 1.71, p=0.0009 and OR 2.21, p=0.0008; OR 1.77, p=0.007 and OR 2.27, p=0.0007, respectively). One SNP (rs988666) had a positive association with PSA in the recessive model (OR 1.92, p=0.04), the other SNP (rs16910295) had same result in the co-dominant model (OR 1.64, p=0.04). One haplotype (Block3_ht5) had a negative association with PSA in the co-dominant model (OR 0.59, p=0.05) and dominant model (OR 0.59, p=0.05).
The association between DKK3 polymorphisms and clinical stage in prostate cancer group
In an analysis according to the clinical stage criteria, five SNPs (rs2403557, rs12295349, rs12288230, rs4586138, and rs7480000) were significantly correlated with clinical stage in each model ( 
The association between DKK3 polymorphisms and pathologic stage in prostate cancer group
The pathological cancer stage was found to be associated with 9 SNPs (rs751580, rs11544817, rs4757519, rs1552796, rs11022098, rs2087882, rs1472190, rs11022095, and rs1472189) and one haplotype (Block1_ht2) (OR2.08 , p=0. 
DIscussIOn
SNPs are the most common polymorphisms in the genomes of many species. The definition of a SNP is a variation of the DNA sequence at a frequency larger than 1% of the allele of a population (5) . In this study, we examined whether genetic variations in the DKK3 gene alter the risk of developing prostate cancer. A total of 53 SNPs located in the DKK3 gene were genotyped in 272 patients with prostate cancer and 173 control subjects with BPH. We found that three SNPs and two haplotypes were significantly associated with prostate cancer risk (p<0.05). Also, we found that two SNPs were markedly significantly associated with prostate cancer aggressiveness (P<0.001). These findings suggest that DKK3 gene polymorphisms may alter susceptibility to prostate cancer and could thus possibly be used as biomarkers for the disease and predictors for aggressivenessin patient with prostate cancer.
The Dickkopf (DKK) family consists of four genes (DKK1-4) and a DKK3-related gene (20) . DKK3 is the most divergent member of the DKK family by DNA sequence, function, and evolution. Unlike the other DKK members, DKK3 does not modulate Wnt signaling (11) and shows no affinity to the Wnt co-receptor LRP5/6 and Kremen (21) . Human DKK3 was proposed to function as a tumor suppressor, since its expression is down-regulated in many types of cancer cells (11) . DKK3 down-regulation has been reported in endometrial cancer (22) , lung cancer (23), gastrointestinal cancer (24) , breast cancer (25) , prostate cancer (26, 27) , and renal carcinomas (28) . In support of the hypothesis that DKK3 functions in prostate as a tumor suppressor, overexpression of DKK3 suppresses cell growth and the invasive capacity of prostate cancer cell lines (26, 27) . Zenzmaier et al. reported that in normal prostate tissue the secreted glycoprotein DKK3 is expressed in the epithelial compartment but expression is lost in BPH and prostate cancer (29) . DKK3 promotes fibroblast proliferation and myofibroblast differentiation and represents a potential therapeutic target for stromal remodeling in BPH and prostate cancer (30) .
To our knowledge, one epidemiological investigation between DKK3 and prostate cancer have been reported. Zenzmaier et al. reported that DKK3 levels in seminal plasma were significantly elevated in biopsy-confirmed prostate cancer patients, because loss of expression seems to be counterbalanced by upregulation of DKK3 expression (31) . In this study, we epidemiologically investigated whether SNPs of the DKK3 gene were related to the risk and aggressiveness of prostate cancer for the first time.
We note that this study has several limitations. Our sample size was relatively small for a case-control association study; it is limited in subgroup analysis. Therefore, the study requires further confirmation in much larger cohorts. However this study included a unique racial population, and the prostate cancer cohorts had a similar clinical characters of a previous Korean study (13) and the control group also had little selection bias due to their exclusion by biopsy. Although control group underwent prostate biopsy which reveals negative malignancy, all the men in the BPH group are potentially at risk for development of prostate cancer and may have latent prostate cancer at time of designation as controls, leading to disease misclassification. In addition we could not evaluate the effect of treatment related to BPH or prostate cancer such as medication or surgery in individuals. For many gene-exposure studies, a key limitation is the quality of the exposure information. Few studies have the ability to examine interactions between pesticide exposure and genetic risk factors Minor allele frequencies and P-values for logistic analyses of three alternative models (co-dominant, dominant and recessive models) controlling for age as covariate are shown. Significant associations are shown in bold face (P-value≤0.05).
for prostate cancer, thus replication of these findings may be difficult. Despite these limitations, the present study provides the first evidence of an important and novel association between DKK3 polymorphisms and the risk for prostate cancer, so will be a basis for future study.
cOncLusIOns
We have observed several positive interactions between DKK3 gene polymorphisms and the risk of prostate cancer in a Korean population for the first time. These findings could be helpful to diagnose and predict the prognosis of prostate cancer. We anticipate that patients' genomic data could be used in clinical practice to investigate associations between the risk of prostate cancer and polymorphisms in the DKK3 gene in the near future.
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